Attached files

file filename
EX-99.1 - Aevi Genomic Medicine, Inc.v220715_ex99-1.htm


 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________________
 
FORM 8-K

Current Report

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
May 4, 2011 (May 4, 2011)
Date of Report (Date of earliest event reported)
 
MEDGENICS, INC.
(Exact name of registrant as specified in its charter)
 
Delaware
1-35112
98-0217544
(State or other jurisdiction of
incorporation or organization)
(Commission File Number)
(I.R.S. Employer
Identification No.)

8000 Towers Crescent Drive, Suite 1300
Vienna, Virginia 22182
 (Address of principal executive offices, zip code)
 
(646) 239-1690
(Registrant’s telephone number, including area code)
 
Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



 
 

 
 
Item 7.01
Regulation FD Disclosure.
 
In accordance with the rules of the AIM Market of the London Stock Exchange, on May 4, 2011 the Company issued a press release summarizing the impact that the Company’s recently completed underwritten public offering had on the interests of the significant shareholders and the directors of the Company and their related parties.  Attached and incorporated by reference as Exhibit 99.1 is a copy of the Company’s press release dated May 4, 2011, with respect to the foregoing information.
 
The information furnished in this report under this Item 7.01, including the Exhibits attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference to such filing.
 
 
Item 9.01  
Financial Statements and Exhibits.
 
 
(d) 
Exhibits.  The following exhibits are filed herewith:

Exhibit No.
Description
99.1
Medgenics, Inc. Press Release dated May 4, 2011 (furnished pursuant to Item 7.01).
 
 
 
 

 

 
SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
MEDGENICS, INC.
 
       
       
 
By:
/s/ Phyllis K. Bellin
 
   
Name: Phyllis K. Bellin
 
   
Title: Director of Finance and Administration
 
 
Date:     May 4, 2011